title: Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.
abstract: Triple-negative breast cancer (TNBC) is a highly aggressive disease characterized by a high number of relapses and poor overall survival. The heterogeneity of the disease and the limited treatment options compared to other breast cancer subtypes mainly explain these clinical outcomes. New biomarkers are urgently needed to improve the management of TNBC. Circulating tumor DNA, identified by tumor-related molecular alterations, could be used in the context of non-invasive "liquid biopsy" and help in TNBC diagnosis and treatment decisions. In this review, we discuss the key issues related to the potential of circulating tumor DNA to improve the management of this disease and the future steps to overcome before its implementation into clinical routine within the next 5 years.
authors.affiliation: a Institut Curie , PSL Research University , Paris , France.|b Circulating Cancer Biomarkers Laboratory, SiRIC, Translational Research Department , Institut Curie , Paris , France.
authors.forename: Adrien
authors.initials: A
authors.lastname: Saliou
authors.affiliation: a Institut Curie , PSL Research University , Paris , France.|c Department of Medical Oncology , Institut Curie , Paris , France.
authors.forename: François-Clément
authors.initials: FC
authors.lastname: Bidard
authors.affiliation: a Institut Curie , PSL Research University , Paris , France.|d INSERM U932 , Institut Curie , Paris , France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Lantz
authors.affiliation: a Institut Curie , PSL Research University , Paris , France.|e INSERM U830 , Institut Curie , Paris , France.
authors.forename: Marc-Henri
authors.initials: MH
authors.lastname: Stern
authors.affiliation: a Institut Curie , PSL Research University , Paris , France.|f Department of Pathology , Institut Curie , Paris , France.
authors.forename: Anne
authors.initials: A
authors.lastname: Vincent-Salomon
authors.affiliation: a Institut Curie , PSL Research University , Paris , France.|b Circulating Cancer Biomarkers Laboratory, SiRIC, Translational Research Department , Institut Curie , Paris , France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Proudhon
authors.affiliation: a Institut Curie , PSL Research University , Paris , France.|c Department of Medical Oncology , Institut Curie , Paris , France.|g Université Paris Descartes , Paris , France.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Pierga
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D004273:DNA, Neoplasm / Q000097:blood / Q000235:genetics*; D005260:Female; D006801:Humans; D009360:Neoplastic Cells, Circulating / Q000473:pathology; D057089:Pathology, Molecular; D011379:Prognosis; D064726:Triple Negative Breast Neoplasms / Q000097:blood / Q000235:genetics* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm
keywords: circulating tumor DNA; diagnosis; liquid biopsy; therapy; triple-negative breast cancer